Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Qualigen Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.72
22.11.22
-
22.11.23
-66.14%
23.11.23

Could be worthwhile Investment >10% per year
buy
Crossject S.A.

Start price
Target price
Perf. (%)
€4.04
12.11.22
€4.50
12.11.23
5.82%
13.11.23

Could be worthwhile Investment >10% per year
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.96
11.11.23
-
11.11.24
-
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.81
05.11.23
-
05.11.24
15.43%
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.01
03.09.23
-
03.09.24
-19.80%
05.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Eledon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.38
29.10.23
€2.80
30.09.25
-
30.10.23

Could be very worthwhile Investment >20% year
buy
Eledon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€1.28
01.10.23
€2.00
30.09.25
14.84%
29.10.23

Could be very worthwhile Investment >20% year
CEL-SCI Corp.

Start price
Target price
Perf. (%)
€1.51
23.10.23
-
23.10.24
-23.18%
28.10.23

Could be worthwhile Investment >10% per year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.47
26.09.23
-
26.09.24
-26.87%
15.10.23

Could be very worthwhile Investment >20% year
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€1.64
30.09.23
€1.00
30.09.24
-9.76%
14.10.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
buy
Cellectis SA ADR

Start price
Target price
Perf. (%)
€2.32
07.10.22
€5.00
07.10.23
-43.97%
08.10.23

Could be worthwhile Investment >10% per year
buy
Valbiotis

Start price
Target price
Perf. (%)
€4.97
05.10.22
€5.50
05.10.23
17.51%
06.10.23

Could be worthwhile Investment >10% per year
buy
Eurobio scientific

Start price
Target price
Perf. (%)
€17.24
05.10.22
€18.00
05.10.23
-24.25%
06.10.23

Could be worthwhile Investment >10% per year
buy
Seelos Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.05
24.06.23
€2.50
24.06.24
-83.41%
01.10.23

Could be very worthwhile Investment >20% year
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.12
27.09.23
-
27.09.24
-35.70%
30.09.23

Risky Investment
Palatin Technologies Inc.

Start price
Target price
Perf. (%)
€1.81
16.09.23
€1.00
16.09.24
-22.10%
30.09.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€5.11
16.09.23
€2.00
16.09.24
-14.09%
30.09.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Pulse Biosciences Inc

Start price
Target price
Perf. (%)
€4.58
13.04.23
-
13.04.26
-14.85%
26.09.23

Risky Investment
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€1.97
03.09.23
-
03.09.24
-21.32%
13.09.23

Risky Investment
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€2.40
11.09.23
-
11.09.24
-22.50%
12.09.23

Probably not worthwhile Investment
buy
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€1.97
03.09.23
€2.50
31.07.25
18.78%
06.09.23

Could be very worthwhile Investment >20% year
buy
Palatin Technologies Inc.

Start price
Target price
Perf. (%)
€4.55
06.09.22
-
06.09.23
-53.45%
06.09.23

ifa systems AG

Start price
Target price
Perf. (%)
€3.16
20.08.23
€0.000
20.08.24
-5.70%
03.09.23

Revenue decline/stagnation expected
Decining EBIT margin than peer group
EBIT decline/stagnation expected
High valuation
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.28
06.08.23
-
06.08.24
-12.50%
20.08.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
HTG Molecular Diagnostics Inc.

Start price
Target price
Perf. (%)
€3.79
27.12.22
-
27.12.23
-90.75%
29.07.23

Capable Management
Risky Investment
No uniques
No Innovation